CUVET Successfully Developed the First Stem Cell Transplantation Technology to Treat Pet Diabetes
BANGKOK, Dec. 2, 2022 /PRNewswire/ -- For the first time in Thailand, a research team from Chula's Faculty of Veterinary Science (CUVET) is the first to have successfully developed a method to culture dog pancreatic cells from stem cells and cell transplantation technology. They aim to test the method in the lab and sick animals suffering from diabetes. ...
Jacobio’s Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
BEIJING, SHANGHAI and BOSTON, Dec. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) will present the results of KRAS G12C inhibitor JAB-21822 as a single agent or in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models in a poster session during the 2022 European Society of Medical Oncology ASIA (ESMO ASIA) Congress...
Innoforce Opens GMP Manufacturing Facility & Corporate Headquarters in Hangzhou, China to Provide CDMO Services for Global Supply of RNA, Cell & Gene Therapies
The new site adds to its capacity in China & US to provide end-to-end process development and global manufacturing services for advanced therapies HANGZHOU, China, Dec. 2, 2022 /PRNewswire/ -- Innoforce, a global provider of end-to-end contract development and manufacturing services (CDMO), today announced that it commenced GMP manufacturing at its new site...
Armis Named Clear Leader in SPARK Matrix for Connected Medical Device Security Solutions
Company recognized for comprehensive and robust asset intelligence platform; ranked highest among competitors for technology excellence and customer impact SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Armis, the leading asset visibility and security company, today announced that it has been named a clear leader for technology excellence and customer impact by Quadrant...
HAVAS HEALTH & YOU EXPANDS CONTENT EXPERTISE THROUGH PARTNERSHIP WITH EVERMED
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COVID-19 dramatically changed the way doctors interact with the health industry – they're looking for more convenient and efficient ways to consume medical information than ever, leading to an uptick in demand for content. To help address the need for more content-focused solutions to reach...
Creating the Leaders of Tomorrow: The Valuable 500 Reach Milestone for ‘Generation Valuable’ on International Day for Persons with Disabilities
Powered by Verizon, the Valuable 500 has enlisted 75 Generation Valuable Mentees and Mentors Launching in January 2023, the Generation Valuable participants will gain access to world-class creative leadership courses and collaborative opportunities with the other multinational corporations taking part in the initial cohort. The programme modules include Creative Leadership, Leadership Identity, Strategic Thinking, Business for Good/ESG, and...
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine. The complete manufacturing of BVX-0918 from a cancer patient's ovarian tumor now validates...
Commercial Dishwashers Destroy Protective Layer in Gut
Residue from rinse agents is left behind on dishes after they are cleaned in professional-grade dishwashers. This damages the natural protective layer in the gut and can contribute to the onset of chronic diseases, as demonstrated by researchers working with organoids at the Swiss Institute of Allergy and Asthma Research, an associated UZH institute. ZURICH, Dec. 1, 2022 /PRNewswire/...
Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826’s Treatment of Female Androgenetic Alopecia in China Was Met
SUZHOU, China, Dec. 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced results of phase II clinical trial of pyrilutamide (KX-826), a potential first-in-class topical drug developed by the company, in China for the treatment of adult female androgeneticalopecia (AGA). In the study, KX-826 has demonstrated...
MGI Cements Its Presence and Contribution in Singapore’s Genomics Landscape at ESMO Asia Congress 2022
SINGAPORE, Dec. 1, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, will join global and Asian cancer professionals at the ESMO Asia Congress 2022 taking place 2-4 December in Singapore. In addition, MGI will introduce a free trial campaign on its latest sequencer DNBSEQ-G99* for early...
